» Articles » PMID: 27920567

Evaluation of BODE Index and Its Relationship with Systemic Inflammation Mediated by Proinflammatory Biomarkers in Patients with COPD

Overview
Journal J Inflamm Res
Publisher Dove Medical Press
Date 2016 Dec 7
PMID 27920567
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: BODE index, a multidimensional grading system which is based on Body mass index, airway Obstruction, Dyspnea scale, and Exercise capacity, has been increasingly used for the evaluation of chronic obstructive pulmonary disease (COPD). Many of the systemic manifestations of COPD are shown to be mediated by elevated levels of proinflammatory biomarkers.

Objective: We aimed to investigate the relationship between the BODE index, its components, disease severity, and proinflammatory biomarkers like C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and interleukin (IL)-6.

Materials And Methods: A cross-sectional study which included 290 clinically stable COPD patients and 80 smoker controls was conducted. Medical history, body mass index, pulmonary function tests, 6-minute walking test, and modified scale of Medical Research Council dyspnea scale were evaluated. BODE scores were determined. Systemic inflammation was evaluated with the measurement of CRP, TNF-α, and IL-6 in the serum samples of all studied subjects. The correlation between inflammatory biomarkers and BODE index was assessed in COPD patients.

Results: We found a significant relationship between COPD stages and BODE index. Our analysis showed significant association between systemic biomarkers and components of the BODE index. Both TNF-α and CRP levels exhibited weak but significant correlation with BODE index. Serum IL-6 concentrations exhibited significant correlation with 6-minute walking test, modified scale of Medical Research Council, and BODE index (=0.201, =0.004; =0.068, =0.001; and =0.530, =0.001, respectively). Also, an inverse and significant correlation was observed between BODE index and FEV1 (=0.567, =0.001). IL-6 exhibited a highly significant and inverse correlation with FEV1 (=-0.580, =0.001).

Conclusion: BODE index should be considered for evaluating patients with COPD. Also, IL-6 seems to be a potential biomarker that may enable determination of the severity and prediction of the course of the disease.

Citing Articles

Assessment of the BODE Index and Its Association With Inflammatory Mediators in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Shah K, Bhat H, Kadam M, Kachalia P, Kuchi Y, Siroha M Cureus. 2024; 16(10):e72172.

PMID: 39583360 PMC: 11582386. DOI: 10.7759/cureus.72172.


Beneficial Bacteria in the Gut Microbiota May Lead to Improved Metabolic and Immunological Status in Chronic Obstructive Pulmonary Disease.

Passos F, de Oliveira L, Jesus F, Zanette D, Neto O, Neves M Med Sci (Basel). 2024; 12(3).

PMID: 39189204 PMC: 11348168. DOI: 10.3390/medsci12030041.


Endothelial dysfunction: The possible link between cardiovascular comorbidities and phenomenon of inflammaging from COPD.

Tudorache E, Fira-Mladinescu O, Traila D, Marc M, Rajnoveanu R, Tofolean D Medicine (Baltimore). 2022; 101(33):e30078.

PMID: 35984178 PMC: 9388037. DOI: 10.1097/MD.0000000000030078.


Nine-Year Follow-Up of Interleukin 6 in Chronic Obstructive Pulmonary Disease - Complementary Results from Previous Studies.

Prudente R, Ferrari R, Mesquita C, Machado L, Franco E, Godoy I Int J Chron Obstruct Pulmon Dis. 2021; 16:3019-3026.

PMID: 34764645 PMC: 8572745. DOI: 10.2147/COPD.S328266.


Benefits of different intensities of pulmonary rehabilitation for patients with moderate-to-severe COPD according to the GOLD stage: a prospective, multicenter, single-blinded, randomized, controlled trial.

He G, Li N, Ren L, Shen H, Liao N, Wen J Int J Chron Obstruct Pulmon Dis. 2019; 14:2291-2304.

PMID: 31631999 PMC: 6790109. DOI: 10.2147/COPD.S214836.


References
1.
Tanni S, Pelegrino N, Angeleli A, Correa C, Godoy I . Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond). 2010; 7:29. PMC: 2891738. DOI: 10.1186/1476-9255-7-29. View

2.
Schols A, Buurman W, Staal van den Brekel A, Dentener M, Wouters E . Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996; 51(8):819-24. PMC: 472555. DOI: 10.1136/thx.51.8.819. View

3.
. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

4.
Balzano G, Stefanelli F, Iorio C, De Felice A, Melillo E, Martucci M . Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med. 1999; 160(5 Pt 1):1486-92. DOI: 10.1164/ajrccm.160.5.9810105. View

5.
Cosio M, Saetta M, Agusti A . Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009; 360(23):2445-54. DOI: 10.1056/NEJMra0804752. View